A B S T R A C T A radioimmunoassay lhas
INTRODUCTION
Efforts to study the physiology of the antidiuretic hormone, arginine vasopressin (AVP),7 have long been hampered by the lack of a simple and sensitive method for measuring the lhormone in blood and other biologic fluids. WAe previously described a procedure for the radioimmunioassay of vasopressin that was capable of measuring the hormiione at physiologic concentrations in relatively small volumes of plasma (1) . Due to certain characteristics of that antiserumn, however, it was necessary to isolate chromatographically and concentrate plasm a vasol)ressin before assay, a requirement that significantly limited the speed and efficiency of the teclhnique.
The ac(luisitioni of a sensitive new antiserum (2) lhas now made possible the development of a much simpler method for radioimnmunoassay of vasopressin in biologic fluids. When used with a simple acetone-extraction technique, this assay permits precise measurements of plasma vasopressin at concentrations as low as 0.5 pg/ml (0.2 AU/ml) in plasma volumes of less than 1 ml. The v-alues obtained are quantitatively similar to those found with our previous more elaborate method (1) and conform well to physiologic expectations in both normal and disordered states of water metabolisnm.
The characteristics of this new assay and its application 1 Abbreviationis used in this paper: AVP, arginine vasopressin; AVPB, natural AVP; AVPG, second preparation of natural AVP; AVPS, synthetic AVP; AVT, synthetic arginine vasotocin; B/F, bound-to-free; Gl-1, antiserum Glick-1; LVP, synthetic lysine vasopressin; OXY, synthetic oxytocin; PAVP, plasma AVP.
to physiologic studies of plasma vasopressin will be described in this paper.
METHODS
Reagents. Antiserum Glick-1 (Gl-1) used in these studies was provided by Dr. Seymour Glick (2) . It was diluted 1:10 with 0.02 M phosphate buffer (pH = 7.4) and stored in glass at -20°C. Working solutions are prepared at 4-mo intervals by diluting the storage stock 1,000-fold with buffer containing 0.02 M phosphate (pH = 7.4), 0.14 M NaCl, and control rabbit serum (10 ,.I/ml).
Natural AVP (AVPB), purified from bovine pituitary (3), was a gift of Dr. Jesse Roth. It has an antidiuretic potency of approximately 400 U/mg, showed no ninhydrinreacting contaminants on ascending paper chromatography in butanol: acetic acid: water, 4: 1: 5, and gave equimolar amounts of the appropriate amino acids on amino acids analysis (1) . When dissolved at a concentration of 1 mg/ml in 0.2 N acetic acid and stored in glass at -20°C, this preparation has shown no change in immunologic potency in over 36 mo. However, more dilute solutions of AVPB, such as the working stock used to prepare the standard curves (500 ng/ml), undergo a significant decrease in immunologic potency when stored for more than 4 mo and, therefore, must be prepared at frequent intervals from the concentrated stock.
A second preparation of natural AVP (AVPG) was provided by Dr. Jack George. It had been purified from bovine pituitary by a modification of the method of Acher, Light, and du Vigneaud (3), using gel filtration instead of ionexchange chromatography. The biologic potency of the AVPG has not been determined but, like the AVPB, it contained no ninhydrin-reacting contaminants on paper chromatography.
Synthetic AVP (AVPs) was purchased from Schwarz/ Mann (Schwarz/Mann Div., Becton, Dickinson & Co., Orangeburg, N. Y.) (lot X-2024). This preparation had a designated pressor potency of 300±20 U/mg, revealed a single ninhyrin-reacting contaminant in several chromatographic systems and, on amino acid analysis, contained a 30% molar excess of unspecified amino acids.
Synthetic arginine vasotocin (AVT), was purchased from Schwarz/Mann (lot X-2129). It had a designated pressor potency of 117+16 U/mg, revealed a trace amount of ninhydrin-reacting contaminant on thin-layer chromatography and, on amino acid analysis, appeared to contain a 16% molar excess of unspecified amino acids. Synthetic lysine vasopressin (LVP), purchased from Nutritional Biochemicals Corp. (Cleveland, Ohio) had a potency of about 100 U/mg. Synthetic oxytocin (OXY) purchased from Mann Research Labs, Inc., (New York) had a potency of 10 U/mg.
["I] AVP was prepared from purified bovine hormone (AVPB) as previously described (1, 4) . This procedure yields a radioiodinated product that is homogeneous on paper chromatography, is 90% bound by excess vasopressin antiserum, and has an immunologically determined specific activity of approximately 1,000 AsCi/,ig. As usually performed, one iodination provides enough [PI]AVP for about 2,000 assays and when stored at -20°C is stable for 4-6 wk.
[1"I]AVP also was prepared from a purified synthetic hormone, AVPs. This preparation yields a radioiodinated product that is only 75-85% bound by excess vasopressin antiserum but gives useful standard curves and unknown Acetone extracts were prepared by mixing 1 ml of the thawed plasma with 2 ml of cold acetone to precipitate plasma proteins. After centrifugation at 2,100 rpm for 40 min, the clear yellow supernate was decanted from the precipitate, thoroughly mixed with 5 ml of cold petroleum ether and centrifuged again, and the top phase was carefully yielded a clear, protein-f ree extract of sufficient volume (approximately 0.7 ml) to permit assay of triplicate 0.2-ml aliquots.
Assay procedutres. Standard curves were prepared in duplicate by mixing 0.05 ml of diluent containing 1,000 cpm of ['5I]AVP (60% counting efficiency), 0.2 ml of diluent containing 0.1-10 pg of AVPB standard, 0.2 ml of 0.14 M saline, and 0.05 ml of a 1:125,000-fold dilution of the Gl-1 antiserum (prepared by diluting the 1:10,000 working stock 12.5-fold with diluent). Unknowns were assayed in triplicate by replacing the 0.2 ml of normal saline wvith an equal volume of acetone-extracted plasma. All samples were incubated in 10 X 75-mm disposable glass tubes (Kimax. Kimble Products) at 4°C for 7 days, then 0.05 ml of 0.14 AM saline containing 16 mg/ml of rabbit -y-globulin was ad(led, and the antibody-["IJ] AVP complex was immediately precipitated by the addition of 0.5 ml of cold polyethylene glycol solution (5). The assay tubes were then centrifuged at 2,100 rpm and 4°C for 1 h, the supernate decanted into 12 X 75-mm disposable glass tubes, and the two fractions counted individually for 10 min or 6,000 couInts in an automated deep-well gamma spectrometer w-ith 60%o counltin- 
RESULTS
Assay sensitivity and specificity. NW'lhen used as described, the GI-1 antiserum can consistently detect a minimum of 0.1 pg (0.04 AU) of the purified AVPB standard, with the most sensitive and precise portion of the standard curve extending to about 2 pg (Fig. 1A) . The other preparation of purified natural vasopressin, AVPG, yielded a displacement curve almost identical with that obtained w-ith AVPB (not showNi1). OIn a weight basis, the AVPs was about 15% less reactive than AVPB (Fig. 1A) , but when compared on the basis of their respective biologic potencies, AVPs appeared to be slightly more immunoreactive than AVPB (Fig. 1B) . Synthetic LVP, AVT, and OXY were, respectively, about 1/3, 1/6, and 1/100 as reactive as AVPB (Fig.  1 B) . Standard AVP was rapidly and completely converted to an immunologically unreactive form by incubation with rat kidney or liver slices but was not effected by incubation with human erythrocytes (Table I ). The addition of 0.2-ml aliquots of saline containilng heparin in concentrations two fold greater than the plasma and acetone in amounts sufficient to cause a strongly positive nitroprusside reaction had no affect on the AVPB standard curve (not shown).
The addition to the assay of 0.2-ml volumes of plasma from normal subjects in various states of water balance produced depressions in the B/F that were equivalent to 3-11 pg of AVP/ml of plasma (Table II) . However, this immunoreactivity did not cross-react like standard AVP ( Fig. 2A) and, when subjected to gel chromatography, demonstrated distinct heterogeneity (Fig. 3A) . (Fig. 3B ). The total immunoreactivity recovered in this fraction (16.7 pg or 73% of the 22.7 pg found in whole plasma) was commensurate with the volume of plasma water recovered during the extraction procedure (0.7 ml from 1 ml of whole plasma). When assayed directly, over a 10-fold range of dilutions, these acetone-extracted plasmas were also immunologically indistinguishable from AVPB (Fig. 2B) .
The amount of non-AVP (acetone precipitable) immunoreactivity in plasma did not correlate with the state of hydration or the amount of true AVP present. When 0.2-ml aliquots of whole and acetone-extracted plasmas were assayed in parallel, the values obtained in the extracts were consistently lower than the values for whole plasma. Under standard assay conditions this difference appeared to be immunologically equivalent to about 2-4 pg/ml of AVP (Table II) Acetone extracts of plasma from normal subjects undergoing maximal water diuresis often contain small but readily detectable amounts of immunoreactivity (vide infra). To characterize this, a large volume of plasma from a water-loaded normal subject, was extracted, desalted, and concentrated by an ion-exchange technique, (6) and the residue was subjected to chromatographic and immunologic tests of identity (Fig. 5 ). pituitary diabetes insipidus whose plasma also contained small amounts of residual immunoreactivitv (not shown).
Recovery of A VP from plasmia. \NVhen physiologic amounts of standard AVP were added to an AVP-deficient plasma and carried through the stanidard extraction and assay procedure, the recovery was virtually complete regardless of the amount of AVrP added (Table III). Allowing the plasma to stanid at room temperature for up to 1 h or repeated freezing anid thawing did not alter the recovery of AVP (Table III) . However, storage of plasmas at -20°C for more than 24 h regularly resulted in a significant decline in immunoassayable AVP (Fig. 6A ). and plasma were collected simultaneously and assayed in parallel both before and after storage, the levels of AVP in serum were almost always lower, by from 10 to 90%, than the levels in plasma (Table IV) .
Precisiont and reproducibility of the assay. The initra- that was markedly subnormal relative to the plasma hypertonicity present (Fig. 7) . However, in the nine samples obtained from four patients in whom the polyuria was due either to primary polydipsia or nephrogenic (vasopressin resistant) diabetes insipidus, the relationship of plasma AVP to plasma osmolalitv did not differ appreciably from that found in normal subjects (Fig. 7) . The relationship of plasma AVP to urinary concentration was also investigated by obtaining simultaneous collections of plasma and urine from 23 healthy subjects in various states of hydration (Fig. 8) . Despite considerable variation in urinary solute excretion (range 0.18-1.3 mosmol/min), a significant correlation between urine osmolality and plasma AVP was found. At plasma AVP concentrations above 5 pg/ml, concentration of the urine was usually maximal (> 1,100 mosmol/kg). Below 5 pg/ml, urinary osmolality (Uosm) decreased in proportion with plasma AVP (PAVP), as described by formula Uosm = 250 (PAVP -0. 25 20 min. Similar patterns of vasopressin clearance were observed after cessation of Pitressin infusion in four other patients with pituitary diabetes insipidus as well as in three normal subjects (Fig. 11) . The mean (+SD) ti for plasma vasopressin in each of the two groups was 22.5±4 and 19+5.6 min, respectively. DISCUSSION The development of a clinically useful radioimmunoassay for plasma vasopressin has proven to be more difficult than for many of the other polypeptide hormones. Although a number of other laboratories have succeeded by a variety of methods in raising antisera to vasopressin (7) (8) (9) (10) (11) (12) (13) (14) (15) , none has been sufficiently sensitive to detect the hormone at the low concentrations (10-M) normally present in plasma. Moreover, when carefully studied, several of these antisera have been found to be unusually susceptible to interference by a The effect of acute hypotension on plasma AVP in a healthy subject. Plasma AVP was determined before, during, and after an i.v. infusion of trimethaphan (Arfonad, Roche Labs., Div.) into a water-loaded adult male. Blood pressure was monitored at the brachial artery by sphygmomanometer and expressed as the mean of the systolic and diastolic values. Plasma osmolality remained at 280 mosmol/kg or less throughout the procedure.
-* * variety of plasma components (1, 12) . Because of these * problems it previously has been necessary to extract chromatographically and concentrate plasma vasopressin before assay, a requirement that significantly limits the usefulness of the technique. The acquisition of a new vasopressin antiserum (2) has now made possible a much simpler and more accurate method for the radioimmunoassay of plasma AVP. The special advantages of this antiserum are its greater sensitivity, which eliminates the need to , concentrate plasma AVP before assay, and a lesser susceptibility to interference by nonhormonal components, which permits the use of much simpler extracf § | | § l | I l tion technique. The sensitivity of the assay, which is 5 10 15 severalfold greater than previous methods, has been pg/mi verified with three different AVP standards (Fig. 1) .
na AVP to urine osmo-Allowing for the small amount of contamination known
Lts with polyuria of direre collected simultane-to be present in the AVPs, the agreement between these described in Fig. 7 . independently prepared standards was quite close. Befrom normal subjects cause of this and other evidence for the purity of the or less (n= 87) showed AVPB standard, we have elected to express our results smolality. The vertical in terms of hormone weight. These can be readily conty limit of the plasma verted to the more commonly used biologic units (microunits per milliliter) simply by multiplying by the potency of our AVPB standard (0.4 MU/pg). Since the assay can ordinarily detect a minimum of 0.1 pg of AVP and the largest volume of sample that can be accommodated is 0.2 ml, the lowest concentration of plasma AVP detectable is 0.5 pg/ml. A further increase in sensitivity, of as much as three-to fourfold, can be obtained by incubating under nonequilibrium conditions., but this approach is not regularly used since the existing sensitivity seems to be adequate to measure physiologic levels of AVP. The high degree of structural specificity shown by this antiserum greatly reduces the likelihood of crossreactions with peptides other than AVP. Even LVP and AVT, which differ from AVP by only one amino acid and have similar biologic properties, were less than 1/3 and 1/6 as reactive in the assay (Fig. lb) . This insensitivity to LVP and AVT is probably of no clinical importance (16) although a recent report claim- ing to identify AVT in the cerebrospinal fluid of man (17) suggests that this point needs to be investigated more fully (ride itifra). The possibility that the assay might react wNxith biologically inactive metabolites of AVP could not be tested directly since the identity of these substances is not vet knowvn. However, we did find that the immuniologic reactivity of AVP was rapidly and totally destroyed by incubation with liver or kidney ( Table I ), organs that are believed to be the principal sites of AVP degradation in vivo (18) . Therefore, unless the inactivation of AVP normally proceeds by a different mechanism, it seems unlikely to result in products with an appreciable activity in our assay.
Despite the specificity showin by our assay, whole l)lasma consistently was found to contain an immunoreactive component that differed chromatographically as well as immunologically from the true AVP present.
This nonhormonal activity, which was qualitatively and quantitatively (lifferent from that seen with our previous alntiserum (1) , constituted a small but significant proportion of the total immilunoreactivity present and appeared to be confined to the macronmolecular fraction of plasma. Although the nature of this atypical imlmunoreactivity has not been completely established, its "activity" in the assay probably is not due to competition for antibody-binding sites, but to a direct effect on the ['25JIAVP itself. This effect, which is often referred to as "damage," can be detected as a progressive decline in the immunologic reactivity of the ['25I]AVP during incubation w ith wlhole )lasma (Fig. 4A) . Since (Fig. 4A) should cause a fall in the apparent B, F of 30-45%, an effect equal to that of 0.5-0.8 pg of AVTP. \Vhen corrected to 1 ml of plasnma, this would give a value for the nonhormlonal "blank" equivalent to about 2.5-4 pg of AVP, an amount similar both to the total activity recovered in the macrolmiolecular fraction (Fig. 3A) and the difference determined by direct assay before and after acetone extraction (Table II) (18) . Although neurophysin, the vasopressin-binding peptide of the posterior pituitary, is found there (19) , its affinity for the hormone is too low to permit significant binding to occur at the concentrations that are normally found in plasma (20) , much less at the fivefold greater dilutions that exist in our assay. Other factors such as the use of heparin, which has been reported to interfere with antigen-antibody reactions in some assays (21) , is not apt to be responsible for the effects observed here since its addition directly to the assay had no effect on the B/F and we find that serum seems to have an even greater tendency than plasma to cause tracer damage. Whatever the mechanism, however, the demonstration of this damage effect is important since it indicates that some kind of corrective measure will probably be necessary for all immunoassays of AVP in plasma or serum, regardless of the vasopressin antiserum used.
The acetone-extraction procedure used here effectively eliminates the interfering substances without altering, quantitatively or qualitatively, the AVP present. Thus, the activity recovered in the acetone extracts was immunologically (Fig. 2B ) and chromatographically (Fig. 3B) indistinguishable from standard AVP and showed no tendency to "damage" ['I]AVP (Fig. 4B) . Although the extraction results in some loss of volume, the concentration of AVP in the extract is not significantly affected, and corrections for recovery are not necessary. This is shown both by the gel chromatography study, in which the recovery of AVP was identical with the recovery of plasma water (Fig. 3) , as well as by the experiments in which known concentrations of standard AVP were added to plasma before extraction and assay (Table III) . The accuracy of this approach depends primarily on the acetoneevacuation step. If significant amounts of acetone remain, the resultant plasma AVP values will be too low due to simple dilution whereas, if the evacuation proceeds too long, the values will be too high due to excess evaporation of water. When properly done, the volume of extract from 1 ml of plasma should be between 0.6 and 0.7 ml and contain no acetone by nitropusside testing. With practice, large numbers of samples can be extracted accurately and reproducibly, as shown both by the precise recoveries (Table III) and the relatively small interassay variability.
The major source of error in the measurement of plasma AVP appears to be the loss of activity that occurs during storage of the samples. Conditions that .&U/min; 0. C., 250 AU/min; D. N., 1,000 ,uU/min; S. C., 1,500 ,U/min; G. F., 1,000 ,U/min; M. T., 2,500 AU/min; and J. D., 5,000 AU/min. Blood for plasmna vasopressin determination was obtained from an indwelling catheter at 5-10-min intervals after stopping the infusion. might normally attend the processing of plasma, such as standing for up to 1 h at room temperature or repeat freezing and thawing, appear to have no effect on the level of immunoassayable AVP present (Table III) . However, storage at -20°C for periods of 24 h or more resulted in a progressive decline in AVP activity in all samples, regardless of the levels initially present (Fig. 6A) . Unlike previous workers, who reported a similar decline in bioassayable plasma AVP during storage (22) , we find that this loss of activity cannot be prevented by addition of dry-ice chips, nor by a variety of other maneuvers such as the use of plastic vials or the addition of Trasylol. Although the problem could be eliminated by assaying each sample immediately after collection, such an approach is not practical for clinical studies, where samples must often be collected at unscheduled or inconvenient times. Accordingly, we have elected to follow a procedure where samples are assayed uniformly after 4-8 wk of storage, a time when all samples seem to have decayed to about the same degree and the rate of further loss of activity is minimal (Fig. 6B) . Although this results in underestimating true plasma AVP levels by 45-50%, variability due simply to temporal differences in decay is minimized, and the values obtained in different individuals, or in the same individual at different times, can be more meaningfully compared.
The validity of this approach to measuring plasma AVP is supported by the clinical results obtained. Plasma AVP concentrations were in the expected range (23) , agreed well with those obtained by our previous more elaborate assay procedure (1) , and appeared to fluctuate appropriately in response to variations in fluid intake. These changes in plasma AVP were found to correlate significantly with changes in plasma osmolalitv (Fig. 7) , a relationship also observed w-ith our previous technique (1) and more recently by others using bioassay (24) as well as immunoassay (12) . As indicated by the equation describing this relationship, the osmoreceptor governing AVP release had a threshold around 280 mosmol/kg and, in agreement with the original conclusions of Verney (25) , was sensitive to increases in plasma osmolality as small as 1%. The sensitivity and reproducibility of this relationship makes it an extremely useful way for interpreting plasma AVP values at least under normovolemic and normotenisive conditions.
Exact comparisons between our values and those obtained by others is difficult because important phvsiologic variables, such as posture or plasnma osmolality, often are not specified. In general, however, the results we obtain appear to be in reasonable agreement with those reported by others using both immunoassay (12) and bioassays (22, (26) (27) (28) (17, 28) . Comparative immunoassay-bioassay studies, in which the reference standards, storage, and extraction procedures are carefully controlled, will be needed to shed light on this interesting possibility. Plasma AVP levels obtained by our method were found to correlate appropriately with the level of urinary concentration in normal subjects (Fig. 8) . A highly significant relationship was observed at plasma -AVP concentrations ranging fromii 0.5 pg/'ml. where urine was usually maximally dilute, to about 5 pg/nil. where maximum urinary concentration was achieved. The ability of nmany water-loaded normal subjects to achieve maximal urinary dilution despite the persistence of small amiiounts of plasimia immunoreactivity deserves special comimient. Although the bioactivity of this material has not been determined, its immunologic and chromatographic similarity to AVP (Fig. 5) coupled with the insensitivity of our assay to biologically inactivated hormiione (Table I) , strongly suggests that this residual immunoreactivity is due to intact AVP. Thus, it is apparently not necessary to suppress plasma AVP to undetectable levels in order to develop a maximiiumii diuresis in normal subjects. The possibility that these low levels of AVP represents a hormone that is biologically inactive due to plasma binding seems unlikely (vide supra) but cannot be excluded at this time.
It is well known that the secretion of vasopressin may be stimulated by a reduction in blood volume (29) . We have found that isovolemic hypotension, produced by ganglionic blockage, also caused a significant rise in plasma AVP that quickly subsided wlhen blood pressure was allowed to return to normal (Fig. 9) . The observation that a reduction in mean arterial blood pressure of only 5% was associated with a small but detectable rise in plasnma AVP suggests that eveen modest changes in blood pressure may have important effects Oll ANVP secretion and should be carefully monitored in studies of hormone function.
The lexvels of plasmla ANP determined by our assay also conformed wNell to pathophysiologic expectations in patients w ith various types of polyuria. In all eight patients with acquired pituitary diabetes insipidus, the levels of plasma immunoreactivity were distinctly subnormal relative to the degree of plasma hyperosmlolality present (Fig. 7) . These levels of immunoreactivity tended to increase slightly during severe dehydration and usually were associated with the appropriate levels of urine osmolality (Fig. 8) suggesting that many patients with acquired pituitar) diabetes insipidus retain some capacity to secrete small but physiologically inadequate amounts of AVP. In contrast, plasma AVP appeared to be completely normal relative to plasma osmolality in patients w-ith primary polydipsia and nephrogenic diabetes insipidus. These findings, which confirm and extend those previously reported (30) , are a further indication that neither chronic over-hydration nor under-hydration appreciably alters the responsiveness of the osmotic control mechanism. U'rine osmo-lality also demonstrated the expected abnormal relationship to plasma AVP in patients with primary polydipsia (31) as well as nephrogenic diabetes insipidus (Fig. 8) .
Pitressin infusion studies demonstrated a clear relationship between the rate of hormone administration and the resultant levels of plasma vasopressin as determined by radioimmunoassay (Figs. 10 and 11) . Even with doses of Pitressin that caused only moderate changes in urinary osmolality, small increases in plasma immunoreactivity could be detected that were proportional both to the rate of hormone infusion and the accompanying changes in urine osmolality (Fig. 10) . Since the Pitressin used did not appear to contain appreciable amounts of nonhormonal immunoreactivity (its immunologic potency was actually about 20% lower than might have been expected on the basis of its designated biologic potency) (Fig. 10) , the observed changes in plasma immunoreactivity were probably due solely to vasopressin. This conclusion is also supported by the similarity between Pitressin clearance rates determined by immunoassay (Fig. 11 ) and those previously observed in man using bioassay (22) . These findings suggest that, unless the other ingredients of Pitressin significantly alter the in vivo metabolism of the hormone, changes in endogenous AVP secretion sufficient to effect significant increases in urine concentration should also be accompanied by readily detectable increases in plasma AVP. Although this conclusion needs to be verified with purer preparations of AVP, it is fully compatible with the clinical results obtained (Fig.  8) .
